PRELUDE THERAPEUTICS INC Proceeds from Sale and Maturity of Marketable Securities
PRELUDE THERAPEUTICS INC (PRLD) reported Proceeds from Sale and Maturity of Marketable Securities of $32.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $24.46M, a 32.43% decline year-over-year.
- PRELUDE THERAPEUTICS INC proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $8.50M, a 88.15% decline year-over-year.
- PRELUDE THERAPEUTICS INC proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $6.40M, a 78.30% decline year-over-year.
- PRELUDE THERAPEUTICS INC proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $40.09M, a 6.31% decline year-over-year.
- PRELUDE THERAPEUTICS INC proceeds from sale and maturity of marketable securities for fiscal 2025 was $154.39M, a 7.48% increase from fiscal 2024.
- PRELUDE THERAPEUTICS INC proceeds from sale and maturity of marketable securities for fiscal 2024 was $143.65M, a 24.59% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC proceeds from sale and maturity of marketable securities for fiscal 2023 was $190.50M, a 6.59% decline from fiscal 2022.
- PRELUDE THERAPEUTICS INC proceeds from sale and maturity of marketable securities for fiscal 2022 was $203.93M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $32.96M 10-Q · filed 2026-08-11 | $39.36M derived: sum of 3 quarters · filed 2026-08-11 | $79.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $8.50M 10-Q · filed 2026-05-12 | $14.90M derived: sum of 2 quarters · filed 2026-05-12 | $54.99M derived: sum of 3 quarters · filed 2026-05-12 | $91.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $46.49M derived: sum of 2 quarters · filed 2026-03-10 | $82.70M derived: sum of 3 quarters · filed 2026-08-11 | $154.39M 10-K · filed 2026-03-10 |
| 2025-09-30 | $40.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $76.30M derived: sum of 2 quarters · filed 2026-08-11 | $147.99M 10-Q · filed 2025-11-12 | $177.49M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $36.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $107.90M 10-Q · filed 2026-08-11 | $137.40M derived: sum of 3 quarters · filed 2026-08-11 | $180.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $71.70M 10-Q · filed 2026-05-12 | $101.19M derived: sum of 2 quarters · filed 2026-05-12 | $143.99M derived: sum of 3 quarters · filed 2026-05-12 | $178.34M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $29.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $72.29M derived: sum of 2 quarters · filed 2026-03-10 | $106.65M derived: sum of 3 quarters · filed 2026-03-10 | $143.65M 10-K · filed 2026-03-10 |
| 2024-09-30 | $42.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $77.15M derived: sum of 2 quarters · filed 2025-11-12 | $114.15M 10-Q · filed 2025-11-12 | $182.40M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $34.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $71.36M 10-Q · filed 2025-08-14 | $139.61M derived: sum of 3 quarters · filed 2025-08-14 | $189.36M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $37.00M 10-Q · filed 2025-05-06 | $105.25M derived: sum of 2 quarters · filed 2025-05-06 | $155.00M derived: sum of 3 quarters · filed 2025-05-06 | $201.50M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $68.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $118.00M derived: sum of 2 quarters · filed 2025-03-10 | $164.50M derived: sum of 3 quarters · filed 2025-03-10 | $190.50M 10-K · filed 2025-03-10 |
| 2023-09-30 | $49.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $96.25M derived: sum of 2 quarters · filed 2024-11-06 | $122.25M 10-Q · filed 2024-11-06 | $157.25M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $46.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $72.50M 10-Q · filed 2024-08-12 | $107.50M derived: sum of 3 quarters · filed 2024-08-12 | $188.85M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $26.00M 10-Q · filed 2024-05-07 | $61.00M derived: sum of 2 quarters · filed 2024-05-07 | $142.35M derived: sum of 3 quarters · filed 2024-05-07 | $187.43M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $35.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $116.35M derived: sum of 2 quarters · filed 2024-02-15 | $161.43M derived: sum of 3 quarters · filed 2024-02-15 | $203.93M 10-K · filed 2024-02-15 |
| 2022-09-30 | $81.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $126.43M derived: sum of 2 quarters · filed 2023-11-01 | $168.93M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $45.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $87.58M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $42.50M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |